News
 
Pharmaceuticals Newsletter - May 21 to May 25, 2012
India Infoline News Service/19:38,May 25, 2012
Piramal Healthcare Limited announced today that Phase I clinical trial data for its investigational new drug candidate P1446A-05 will be presented at the Annual Meeting of the American Society for Clinical Oncology (ASCO) being convened in Chicago from June 1-5, 2012.
list India Infoline Weekly Newsletter - May 25, 2012
list Pfizer recalls Advil bottles from distributor centers
list Teva outlines financial estimates for 2012
list Ranbaxy hires advisers for resolving consent decree with USFDA

Calendar

May-2012
M T W T F S S
21 22 23 24 25 26 27
Economic Events
list Corporate Service Price (YoY)
list Hometrack Housing Survey (MoM)
Results
list No result today
IPO
listNo IPO today
 

Solid Q4 earnings boost Akzo Nobel India

Capital Market / 12:13 , May 12, 2011

Akzo Nobel India gained 2.40% to Rs 859 at 12:10 IST on BSE, after net profit surged 221.4% to Rs 57.82 crore on 21.4% rise in net sales to Rs 266.60 crore in Q4 March 2011 over Q4 March 2010.

The company announced the results after market hours on Wednesday, 11 May 2011.

Meanwhile, the BSE Sensex was down 91.55 points, or 0.49%, to 18,493.41.

On BSE, 1,557 shares were traded in the counter as against average daily volume of 2,434 shares over the past two weeks.

The stock hit a high of Rs 865 and a low of Rs 840 so far during the day.

Akzo Nobel India's net profit rose 10.9% to Rs 176.65 crore on 15.9% rise in net sales to Rs 1087.59 crore in the year ended March 2011 over the year ended March 2010.

Akzo Nobel India's board recommended a dividend of Rs 18 per share for the year ended March 2011.

Commenting on the results, Amit Jain, managing director of the company said the profits for the year ended March 2011 (FY 2011) grew by 11%, despite substantial reduction in investment income, due to operating income growth and some one-off gains. During FY 2011, the company earned Rs 11.28 crore on profit on sale of national starch business.

 



Rate This Article Rate 1 Rate 2 Rate 3 Rate 4 Rate 5